Plato BioPharma Inc. (PBI) Founder and CEO, Dr. Craig F. Plato, announced the co-authorship of a research paper appearing in the 12 March, 2014 issue of Science Translational Medicine. The paper, titled “Intestinal Inhibition of the Na+/H+Exchanger 3 Prevents Cardiorenal Damage in Rats and Inhibits Na+ Uptake in Humans” describes the effects of tenapanor, a compound that reduces the absorption of dietary sodium in the GI tract. Ardelyx, a Fremont-based biotechnology company, and their pharmaceutical…
Read More